Capricor Therapeutics (CAPR) Tops Q3 EPS by 5c

Capricor Therapeutics (NASDAQ: CAPR) reported Q3 EPS of ($0.25), $0.05 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $6.19 million versus the consensus estimate of $3.15 million.

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.

You May Also Be Interested In

• Target (TGT) Tops Q2 EPS by $1.78, Beats on Revenue; Offers FY27 EPS Guidance
• Iridex Corp (IRIX) Misses Q2 EPS by 5c
• Jack Henry (JKHY) Tops Q4 EPS by 13c